300685 Stock Overview
A diagnostic company, focuses on development and commercialization of diagnostics product for oncology in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
No risks detected for 300685 from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Amoy Diagnostics Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥23.40 |
| 52 Week High | CN¥28.79 |
| 52 Week Low | CN¥14.60 |
| Beta | 0.78 |
| 1 Month Change | -6.85% |
| 3 Month Change | 21.50% |
| 1 Year Change | 11.48% |
| 3 Year Change | -45.12% |
| 5 Year Change | -5.45% |
| Change since IPO | 4.26% |
Recent News & Updates
Recent updates
Shareholder Returns
| 300685 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | -2.8% | -0.7% | 0.4% |
| 1Y | 11.5% | -18.4% | 12.3% |
Return vs Industry: 300685 exceeded the CN Biotechs industry which returned -18.4% over the past year.
Return vs Market: 300685 matched the CN Market which returned 12.3% over the past year.
Price Volatility
| 300685 volatility | |
|---|---|
| 300685 Average Weekly Movement | 8.4% |
| Biotechs Industry Average Movement | 8.9% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in CN Market | 13.0% |
| 10% least volatile stocks in CN Market | 5.8% |
Stable Share Price: 300685 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 300685's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 1,119 | Jiemin Luo | www.amoydx.com |
Amoy Diagnostics Co., Ltd., a diagnostic company, focuses on development and commercialization of diagnostics product for oncology in China and internationally. It offers AmoyDx homologous recombination deficiency (HRD) focus panel solutions for evaluating PARP inhibitor-related biomarkers and advancing targeted treatment research in ovarian cancer; AmoyDx HRD complete panel to detect genetic aberrations across HRR genes and HRD status; AmoyDx master panel, a CGP assay; AmoyDx BRCA Pro panel that covers various protein coding regions, intron/exon boundaries, select introns, and UTR regions of the BRCA1 and BRCA2 genes; AmoyDx handle classic NGS panel to detect multiple gene mutations in cancer patients for treatment; and AmoyDx essential NGS panel to detect EGFR, ALK, ROS1, RET, KRAS, NRAS, PIK3CA, BRAF, HER2, and MET genes in patients with non-small cell lung cancer and colorectal cancer using FFPE or liquid biopsy samples. The company also provides AmoyDx handle HRR NGS panel for detection of somatic and germline variants; AmoyDx pan lung cancer PCR panel, a tissue-based real-time qPCR assay for in vitro diagnostics; AmoyDx myeloid blood cancer panel; AmoyDx comprehensive panel, a sequencing-based test capable of detecting a range of alterations; AmoyDx PD-L1 (E1L3N) assay; and AmoyDx handle melanoma NGS panel to detect single nucleotide variants, insertions, and deletions within pivotal melanoma tumor genes.
Amoy Diagnostics Co., Ltd. Fundamentals Summary
| 300685 fundamental statistics | |
|---|---|
| Market cap | CN¥9.22b |
| Earnings (TTM) | CN¥315.02m |
| Revenue (TTM) | CN¥1.18b |
29.3x
P/E Ratio7.8x
P/S RatioIs 300685 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300685 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.18b |
| Cost of Revenue | CN¥190.33m |
| Gross Profit | CN¥993.55m |
| Other Expenses | CN¥678.53m |
| Earnings | CN¥315.02m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.80 |
| Gross Margin | 83.92% |
| Net Profit Margin | 26.61% |
| Debt/Equity Ratio | 2.9% |
How did 300685 perform over the long term?
See historical performance and comparisonDividends
0.6%
Current Dividend Yield19%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 01:52 |
| End of Day Share Price | 2024/12/25 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Amoy Diagnostics Co., Ltd. is covered by 16 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yolanda Yin | China Galaxy International Securities (Hong Kong) |
| Pei Cheng | China Galaxy Securities Co., Ltd. |
| Jin Zhang | China International Capital Corporation Limited |